FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Drug metabolism and disposition: the biological fate of chemicals1997; 25(10); 1130-1136;

In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse.

Abstract: As domestic animals such as cat, horse, and dog increasingly become the clinical targets for drug discovery programs, the need to understand how these animals metabolize xenobiotics becomes more important. In the present study, substrates and inhibitors that were reported to be selective for particular P450 isozymes were used as probes to study in vitro metabolism in horse, dog, cat, and human liver microsomes. Seven selective catalytic activity markers for cytochrome P450-mediated reactions were measured: phenacetin O-deethylase (P4501A1/2), coumarin 7-hydroxylase (P4502A6), tolbutamide hydroxylase (P4502C8/9), S-mephenytoin 4'-hydroxylase (P4502C19), dextromethorphan O-demethylase (P4502D6), chlorzoxazone 6-hydroxylase (P4502E1), and testosterone 6beta-hydroxylase (P4503A4). Metabolic activity was found in every species with each substrate. Under the conditions of this study, it was observed that no one species was more active for any given substrate. However, rather large interspecies differences were observed. There was no marked sex difference in the way the various species metabolized the different substrates. The effect of selective P450 inhibitors on the various activities was tested with furafylline (P4501A2), mouse monoclonal antibody inhibitory to CYP2A6, sulfaphenazole (P4502C9), tranylcypromine (P4502C19), quinidine (P4502D6), diethyldithiocarbamate (P4502E1), and troleandomycin (P4503A4). In most cases, these inhibitors were effective to varying degrees against the activity seen in horse, dog, and cat liver microsomes. However, even at high concentrations, furafylline did not inhibit phenacetin O-deethylase activity in cat and troleandomycin did not affect testosterone 6beta-hydroxylase activity in horse. Sulfaphenazole was not tested in dog and cat because of the low tolbutamide hydroxylase activity. Overall, these results show that there are also large interspecies differences in the way the selective P450 inhibitors affect the in vitro metabolism of the various substrates in horse, dog, and cat liver microsomes.
Get Full Text
Publication Date: 1997-10-09 PubMed ID: 9321515
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article is about a study that explores the metabolism of xenobiotics in domestic animals and humans using certain markers and inhibitors for cytochrome P450-mediated reactions to understand interspecies differences.

Objective of Research

The primary objective of the research is to study the metabolism of xenobiotics, substances foreign to a living organism, in domestic animals (cat, horse, and dog) which are increasingly becoming clinical targets for drug discovery programs. An understanding of how these animals metabolize these substances will help in creating effective drugs for them.

Methodology

  • The research uses substrates and inhibitors that are known to be selective for particular P450 isozymes as probes to study in vitro metabolism in horse, dog, cat, and human liver microsomes.
  • Seven selective catalytic activity markers for cytochrome P450-mediated reactions were measured, including phenacetin O-deethylase, coumarin 7-hydroxylase, tolbutamide hydroxylase, S-mephenytoin 4′-hydroxylase, dextromethorphan O-demethylase, chlorzoxazone 6-hydroxylase, and testosterone 6beta-hydroxylase.
  • The research also analyzed the effect of selective P450 inhibitors on various activities using furafylline, mouse monoclonal antibody inhibitory to CYP2A6, sulfaphenazole, tranylcypromine, quinidine, diethyldithiocarbamate, and troleandomycin.

Results

  • The study found metabolic activity in all species with each substrate, and observed large interspecies differences.
  • No significant sex difference was noted in the way the various species metabolized the different substrates.
  • For most cases, these inhibitors were effective to varying degrees against the activity seen in horse, dog, and cat liver microsomes. However, furafylline did not inhibit phenacetin O-deethylase activity in cats and troleandomycin did not affect testosterone 6beta-hydroxylase activity in horses. Sulfaphenazole was not tested in dog and cat due to low tolbutamide hydroxylase activity.

Conclusion

The results reveal large interspecies differences in the way the selective P450 inhibitors derive the in vitro metabolism. Understanding these differences is vital for successful drug discovery programs targeting these animals.

Cite This Article

APA
Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA. (1997). In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos, 25(10), 1130-1136.

Publication

Drug metabolism and disposition: the biological fate of chemicals
ISSN: 0090-9556
NlmUniqueID: 9421550
Country: United States
Language: English
Volume: 25
Issue: 10
Pages: 1130-1136

Researcher Affiliations

Chauret, N
  • Merck Frosst Centre for Therapeutic Research, Pointe-Claire-Dorval, Q, Canada.
Gauthier, A
    Martin, J
      Nicoll-Griffith, D A

        MeSH Terms

        • Adolescent
        • Adult
        • Animals
        • Cats
        • Cytochrome P-450 Enzyme Inhibitors
        • Cytochrome P-450 Enzyme System / metabolism
        • Dogs
        • Enzyme Inhibitors / pharmacology
        • Horses
        • Humans
        • In Vitro Techniques
        • Microsomes, Liver / drug effects
        • Microsomes, Liver / metabolism
        • Middle Aged

        Citations

        This article has been cited 25 times.
        1. Shapter FM, Granados-Soler JL, Stewart AJ, Bertin FR, Allavena R. Equine Crofton Weed (Ageratina spp.) Pneumotoxicity: What Do We Know and What Do We Need to Know?. Animals (Basel) 2023 Jun 23;13(13).
          doi: 10.3390/ani13132082pubmed: 37443880google scholar: lookup
        2. Sugimoto K, Sugita K, Orito K, Fujii Y. Repeated-Dose Pharmacodynamics of Pimobendan in Healthy Cats. Animals (Basel) 2022 Apr 11;12(8).
          doi: 10.3390/ani12080981pubmed: 35454228google scholar: lookup
        3. Schneider D, Bier D, Holschbach M, Bauer A, Neumaier B. Species Differences in Microsomal Metabolism of Xanthine-Derived A(1) Adenosine Receptor Ligands. Pharmaceuticals (Basel) 2021 Mar 18;14(3).
          doi: 10.3390/ph14030277pubmed: 33803861google scholar: lookup
        4. Giantin M, Rahnasto-Rilla M, Tolosi R, Lucatello L, Pauletto M, Guerra G, Pezzato F, Lopparelli RM, Merlanti R, Carnier P, Capolongo F, Honkakoski P, Dacasto M. Functional impact of cytochrome P450 3A (CYP3A) missense variants in cattle. Sci Rep 2019 Dec 23;9(1):19672.
          doi: 10.1038/s41598-019-56271-8pubmed: 31873175google scholar: lookup
        5. Visser M, Weber KL, Lyons LA, Rincon G, Boothe DM, Merritt DA. Identification and quantification of domestic feline cytochrome P450 transcriptome across multiple tissues. J Vet Pharmacol Ther 2019 Jan;42(1):7-15.
          doi: 10.1111/jvp.12708pubmed: 30171610google scholar: lookup
        6. Smith RL, Cohen SM, Fukushima S, Gooderham NJ, Hecht SS, Guengerich FP, Rietjens IMCM, Bastaki M, Harman CL, McGowen MM, Taylor SV. The safety evaluation of food flavouring substances: the role of metabolic studies. Toxicol Res (Camb) 2018 Jul 1;7(4):618-646.
          doi: 10.1039/c7tx00254hpubmed: 30090611google scholar: lookup
        7. Thames BE, Lovvorn J, Papich MG, Wills R, Archer T, Mackin A, Thomason J. The effects of clopidogrel and omeprazole on platelet function in normal dogs. J Vet Pharmacol Ther 2017 Apr;40(2):130-139.
          doi: 10.1111/jvp.12340pubmed: 27452307google scholar: lookup
        8. Nair V, Okello M. Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids. Molecules 2015 Jul 13;20(7):12623-51.
          doi: 10.3390/molecules200712623pubmed: 26184144google scholar: lookup
        9. Nair V, Okello MO, Mangu NK, Seo BI, Gund MG. A novel molecule with notable activity against multi-drug resistant tuberculosis. Bioorg Med Chem Lett 2015 Mar 15;25(6):1269-73.
          doi: 10.1016/j.bmcl.2015.01.050pubmed: 25677656google scholar: lookup
        10. Okello M, Mishra S, Nishonov M, Nair V. Notable difference in anti-HIV activity of integrase inhibitors as a consequence of geometric and enantiomeric configurations. Bioorg Med Chem Lett 2013 Jul 15;23(14):4112-6.
          doi: 10.1016/j.bmcl.2013.05.050pubmed: 23746474google scholar: lookup
        11. Seo BI, Uchil VR, Okello M, Mishra S, Ma XH, Nishonov M, Shu Q, Chi G, Nair V. Discovery of a Potent HIV Integrase Inhibitor that Leads to a Prodrug with Significant anti-HIV Activity. ACS Med Chem Lett 2011 Oct 5;2(12):877-881.
          doi: 10.1021/ml2001246pubmed: 22328963google scholar: lookup
        12. Baillie TA, Rettie AE. Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet 2011;26(1):15-29.
          doi: 10.2133/dmpk.dmpk-10-rv-089pubmed: 20978360google scholar: lookup
        13. Stadel R, Yang J, Nalwalk JW, Phillips JG, Hough LB. High-affinity binding of [3H]cimetidine to a heme-containing protein in rat brain. Drug Metab Dispos 2008 Mar;36(3):614-21.
          doi: 10.1124/dmd.107.017889pubmed: 18094038google scholar: lookup
        14. Amunom I, Stephens LJ, Tamasi V, Cai J, Pierce WM Jr, Conklin DJ, Bhatnagar A, Srivastava S, Martin MV, Guengerich FP, Prough RA. Cytochromes P450 catalyze oxidation of alpha,beta-unsaturated aldehydes. Arch Biochem Biophys 2007 Aug 15;464(2):187-96.
          doi: 10.1016/j.abb.2007.05.019pubmed: 17599801google scholar: lookup
        15. Gusson F, Carletti M, Albo AG, Dacasto M, Nebbia C. Comparison of hydrolytic and conjugative biotransformation pathways in horse, cattle, pig, broiler chick, rabbit and rat liver subcellullar fractions. Vet Res Commun 2006 Apr;30(3):271-83.
          doi: 10.1007/s11259-006-3247-ypubmed: 16437303google scholar: lookup
        16. Liu Y, Yang L. Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics. J Zhejiang Univ Sci B 2006 Feb;7(2):99-106.
          doi: 10.1631/jzus.2006.B0099pubmed: 16421964google scholar: lookup
        17. Iyer RP, Jin Y, Roland A, Morrey JD, Mounir S, Korba B. Phosphorothioate di- and trinucleotides as a novel class of anti-hepatitis B virus agents. Antimicrob Agents Chemother 2004 Jun;48(6):2199-205.
          doi: 10.1128/AAC.48.6.2199-2205.2004pubmed: 15155222google scholar: lookup
        18. Gibbs MA, Hosea NA. Factors affecting the clinical development of cytochrome p450 3A substrates. Clin Pharmacokinet 2003;42(11):969-84.
          doi: 10.2165/00003088-200342110-00003pubmed: 12908853google scholar: lookup
        19. Donato MT, Castell JV. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin Pharmacokinet 2003;42(2):153-78.
          doi: 10.2165/00003088-200342020-00004pubmed: 12537515google scholar: lookup
        20. Furuta S, Akagawa N, Kamada E, Hiyama A, Kawabata Y, Kowata N, Inaba A, Matthews A, Hall M, Kurimoto T. Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential. Br J Clin Pharmacol 2002 Sep;54(3):295-303.
          doi: 10.1046/j.1365-2125.2002.01649.xpubmed: 12236850google scholar: lookup
        21. Zuber R, Anzenbacherová E, Anzenbacher P. Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 2002 Apr-Jun;6(2):189-98.
          doi: 10.1111/j.1582-4934.2002.tb00186.xpubmed: 12169204google scholar: lookup
        22. Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001 Nov;52(5):547-53.
          doi: 10.1046/j.0306-5251.2001.01474.xpubmed: 11736863google scholar: lookup
        23. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 2000 Nov;50(5):427-40.
          doi: 10.1046/j.1365-2125.2000.00272.xpubmed: 11069437google scholar: lookup
        24. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, Cohen MS. Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999 Aug;43(8):1817-26.
          doi: 10.1128/AAC.43.8.1817pubmed: 10428898google scholar: lookup
        25. Rochat B, Paus E, Maitre C, Baumann P. Citalopram in vitro metabolism in a Beagle dog: A role for CYP2D15 in the production of toxic didesmethylcitalopram?. Vet Med (Praha) 2023 Apr;68(4):135-144.
          doi: 10.17221/65/2022-VETMEDpubmed: 37982088google scholar: lookup
        Subscribe to our newsletter
        Join 99,780 horse owners like you who receive our email updates on horse health and nutrition.